42 patents
Utility
Galectin-3 inhibiting c-glycosides
16 Jan 24
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed.
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Filed: 26 Dec 19
Utility
Methods for Treating Acute Myeloid Leukemia and Related Conditions
28 Dec 23
Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I) a prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
Helen M. THACKRAY, Henry H. FLANNER, Curt D. WOLFGANG
Filed: 7 Jun 23
Utility
Methods of Mobilizing Marrow Infiltrating Lymphocytes and Uses Thereof
28 Dec 23
Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer.
John L. Magnani, William E. Fogler
Filed: 1 Jun 23
Utility
Heterobifunctional inhibitors of E-selectin and galectin-3
19 Dec 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed.
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Indranath Ghosh, Jason Nogueira
Filed: 26 Dec 19
Utility
E-selectin Targeting Agents
16 Nov 23
E-selectin ligands which are useful for the synthesis of E-selectin ligand-bearing carriers, wherein said E-selectin ligand-bearing carriers are directly or indirectly linked to or associated with at least one therapeutic agent, diagnostic agent, imaging agent, or radiopharmaceutical are described herein.
John L. MAGNANI, John M. PETERSON, William E. FOGLER, Myung-Gi BAEK
Filed: 17 Sep 21
Utility
Highly Potent Multimeric E-selectin Antagonists
16 Nov 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. MAGNANI, John M. PETERSON, Myung-Gi BAEK
Filed: 19 Jul 23
Utility
Highly potent multimeric e-selectin antagonists
10 Oct 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed.
John L. Magnani, John M. Peterson, Myung-Gi Baek
Filed: 15 Jun 21
Utility
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
1 Aug 23
Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer.
John L. Magnani, William Fogler
Filed: 29 Nov 18
Utility
Methods for treating acute myeloid leukemia and related conditions
25 Jul 23
Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
Helen M. Thackray, Henry H. Flanner, Curt D. Wolfgang
Filed: 4 Mar 19
Utility
Compositions and Methods for Overcoming Microenvironment-mediated Resistance Via E-selectin Targeting
13 Jul 23
Methods for treating a cancer (such as, e.g., acute myeloid leukemia) comprising administering to a subject (such as, e.g., a subject who has acquired resistance to a therapy comprising at least one antineoplastic agent and/or at least one hypomethylating agent) at least one E-selectin antagonist, wherein the subject is further administered at least one antineoplastic agent (such as, e.g., venetoclax) and/or at least one hypomethylating agent are disclosed.
John L. MAGNANI, William E. FOGLER, Theodore SMITH
Filed: 11 Jun 21
Utility
Treatment of Acute Respiratory Distress Syndrome and Related Conditions with Antagonists of E-selectin
11 May 23
Methods for treating diseases, disorders, and/or conditions associated with COVID-19 comprising administering at least one E-selectin antagonist and/or composition comprising the same are disclosed.
John L. MAGNANI, William E. FOGLER, Armand F. GIRARD
Filed: 26 Mar 21
Utility
Combination of T-cell Checkpoint Inhibitors with Inhibitors of E-selectin or CXCR4, or with Heterobifunctional Inhibitors of Both E-selectin and CXCR4
27 Apr 23
Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C-X-C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
John L. Magnani, William E. Fogler
Filed: 28 Jul 22
Utility
E-selectin Antagonist Compounds, Compositions, and Methods of Use
30 Mar 23
Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand.
John L. MAGNANI, Arun K. SARKAR, Myung-Gi BAEK, Frank E. ANDERSON, III, Yanhong LI
Filed: 20 Apr 22
Utility
GALECTIN-3 Inhibiting C-glycoside Ketones, Ethers, and Alcohols
23 Mar 23
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of galectin-3 to ligands are disclosed.
John L. MAGNANI, John M. PETERSON, Yusuf U. VOHRA, lndranath GHOSH, Jason NOGUEIRA, Arun K. SARKAR, Debatosh MAJUMDAR
Filed: 23 Dec 20
Utility
Galactose-linked Multimeric Glycomimetic Inhibitors of E-selectins, GALECTIN-3, And/or CXCR4 Chemokine Receptors
16 Mar 23
John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Myung-Gi BAEK, Hong-Woon YANG
Filed: 21 Apr 20
Utility
Heterobifunctional inhibitors of E-selectin and galectin-3
10 Jan 23
John L. Magnani, John M. Peterson, Arun K. Sarkar, Yusufbhai U. Vohra, Hong-Woon Yang
Filed: 28 Dec 18
Utility
Process for Preparing an E-selectin Inhibitor Intermediate
15 Sep 22
A process is provided for the synthesis of an intermediate of Formula 15 which is useful in the synthesis of E-selectin inhibitors.
Henry H. Flanner, John M. Peterson, Arun K. Sarkar, John L. Magnani, Gerd Osswald, Daniel Schwizer, Marc Lanz, Andreas Helmut Bernd Kyas
Filed: 18 Aug 20
Utility
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
6 Sep 22
Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C—X—C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.
John L. Magnani, William E. Fogler
Filed: 7 Aug 17
Utility
Methods for Use of Gene Expression As an Indicator of E-selectin Inhibitor Efficacy and Clinical Outcome for Multiple Tumor Types
25 Aug 22
Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome.
John L. MAGNANI, William E. FOGLER, Helen M. THACKRAY, Eric J. FELDMAN, David STEWART
Filed: 12 Jul 20
Utility
Use of E-selectin Antagonists to Enhance the Survival of Reconstituted, Bone Marrow-depleted Hosts
25 Aug 22
Hematopoietic stem cell (HSC) transplantation is a promising treatment for patients with various hematological diseases, immunodeficiency, autoimmune disorders, and other genetic disorders.
John L. MAGNANI, William E. FOGLER
Filed: 31 Jul 20